Free Fatty Acids Link Residual Lipid and Thrombotic Risk via Impairment of Aspirin Antiplatelet Effects

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Thrombosis Research

Background:

• Residual cardiovascular risk persists despite therapy, linked to lipid abnormalities and impaired aspirin response (high on-treatment platelet reactivity).
• The interplay between lipids like low-density lipoprotein (LDL) and free fatty acids (FFA) and aspirin's antiplatelet efficacy remains unclear.

Purpose of the Study:

• To investigate the potential link between lipid profiles (LDL, FFA) and impaired aspirin response in cardiovascular disease (CVD) patients.
• To determine if LDL and FFA affect aspirin's pharmacodynamic response at the cyclooxygenase (COX) level.
• To assess the impact of statin therapy on aspirin's antiplatelet effects in the context of lipid levels.

Main Methods:

• In vitro incubation of healthy donor blood with LDL, FFA, and acetylsalicylic acid, measuring arachidonic acid (AA)-induced platelet aggregation, thromboxane (TX) formation, and COX-1 activity.
• Cross-sectional analysis of 612 aspirin-treated CVD patients, measuring aspirin's antiplatelet effects, LDL, and FFA concentrations.
• Correlation analysis between lipid levels, platelet aggregation, and statin medication status.

Main Results:

• In vitro, LDL and FFA impaired aspirin's antiplatelet effects.
• In patients, higher FFA levels were associated with high on-treatment platelet reactivity to aspirin.
• FFA and LDL levels correlated with increased AA-induced platelet aggregation.
• Statin medication was associated with improved aspirin antiplatelet effects and decreased AA-induced platelet aggregation.

Conclusions:

• A link exists between residual lipid burden and thrombotic risk in CVD patients.
• LDL and FFA negatively impact aspirin's pharmacodynamic response by affecting COX activity.
• Statin therapy demonstrates a beneficial effect on aspirin's antiplatelet activity, potentially mitigating residual thrombotic risk.